[ibd-display-video id=2385970 width=50 float=left autostart=true] The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. Winning stocks often have a 95 or higher grade in the early stages of a new price run.
Zoetis is currently extended beyond a proper buy zone after breaking out from a 63.95 buy point in a flat base.
The stock earns a 96 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 96% of all stocks.
Its Accumulation/Distribution Rating of A- shows heavy buying by institutional investors over the last 13 weeks.
In Q4, the company posted 47% earnings growth. It has now posted accelerating EPS growth for two consecutive quarters. Top line growth climbed 14%, up from 9% in the prior report. The company has now posted rising growth in each of the last two reports.
Zoetis earns the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ) is the No. 1-ranked stock within the group.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.